Visugromab Antibody
Visugromab (CTL-002) is a GDF-15-neutralizing monoclonal antibody. It demonstrates synergistic antitumor efficacy in combination with anti-PD-1 therapy like Nivolumab, showing promise in preclinical models for treating PD-1/PD-L1 refractory metastatic cancers.
Product Specifications
Product Name Alternative
PDL1, PD-L1, CTL002, CTL-002, PD1/PDL1, PD1, PD-1
Target
TGF-beta/Smad, PD-1/PD-L1
Clonality
Monoclonal
Conjugation
Unconjugated
Field of Research
Cell Biology, Immunology & Inflammation, Stem Cell & Developmental Biology
Concentration
5 mg/mL
Purity
95.00% (May vary between batches)
Molecular Weight
144.50 kDa
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog